Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 06.07.2026 1 Anticancer Res 12 BJU Int 5 BMC Cancer 9 BMC Urol 1 Br J Cancer 2 Cancer Imaging 1 Cancer Res 1 Endocrinology 3 Eur Urol 5 J Nucl Med 1 Lancet Oncol 3 Prostate 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. TSAI YS, Lee PH, Jou YC, Tsai HT, et al
   Two Arms-one Assisted Port Extraperitoneal Robot-assisted Radical Prostatectomy: A Simplified, Safe, Alternative Technique.
   Anticancer Res. 2026;46:4011-4020.
   PubMed         Abstract available
   
   

   
   BJU Int

2. PASANEN N, Talala K, Remmers S, Tammela TLJ, et al
   Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
   BJU Int. 2026 Jul 4. doi: 10.1111/bju.70380.
   PubMed         Abstract available
   
   
3. HOLSCHER T, Lohaus F, Koi L, Kotzerke J, et al
   Ablative radiotherapy in castration-resistant prostate cancer.
   BJU Int. 2026 Jul 2. doi: 10.1111/bju.70368.
   PubMed         Abstract available
   
   
4. BEATRICI E, de Angelis M, Almeida-Magana R, Al-Hammouri T, et al
   Delphi consensus on ex vivo fluorescence confocal microscopy in robot-assisted radical prostatectomy.
   BJU Int. 2026;138 Suppl 1.
   PubMed         Abstract available
   
   
5. FANG L, Mayor N, Light A, Silvanto A, et al
   Deep learning for fluorescence confocal microscopy image interpretation in radical prostatectomy.
   BJU Int. 2026;138 Suppl 1.
   PubMed         Abstract available
   
   
6. GAYA JM, Verri P, Gallioli A, Uleri A, et al
   Margin evaluation with fluorescence confocal microscopy during minimally invasive radical prostatectomy.
   BJU Int. 2026;138 Suppl 1:S121-S127.
   PubMed         Abstract available
   
   
7. YOUNIS SK, Watfa M, Wang L, Daher K, et al
   Same-day fluorescence confocal microscopy of MRI-targeted prostate biopsies: A feasibility study.
   BJU Int. 2026;138 Suppl 1.
   PubMed         Abstract available
   
   
8. DE ANGELIS M, Beatrici E, Penaranda NR, Frego N, et al
   Intraoperative margin assessment using fluorescence confocal microscopy during robot-assisted radical prostatectomy: a first experience.
   BJU Int. 2026;138 Suppl 1.
   PubMed         Abstract available
   
   
9. CLARE K, Haines K, Littlefield J, Mandel A, et al
   Use of parallel fluorescent confocal microscopy for detection of prostatic adenocarcinoma.
   BJU Int. 2026;138 Suppl 1.
   PubMed         Abstract available
   
   
10. SKOK K, Scheipner L, Mannweiler S, Kashofer K, et al
    Feasibility and workflow analysis of confocal microscopy in robot-assisted prostatectomy.
    BJU Int. 2026;138 Suppl 1.
    PubMed         Abstract available
    
    
11. VAN DRUMPT J, Govers T, Almeida-Magana R, Baas D, et al
    The cost-effectiveness of intraoperative margin assessment strategies during radical prostatectomy.
    BJU Int. 2026;138 Suppl 1.
    PubMed         Abstract available
    
    
12. VAN DRUMPT J, Baas D, Aben K, van Leenders A, et al
    Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy.
    BJU Int. 2026;138 Suppl 1.
    PubMed         Abstract available
    
    
13. ALMEIDA-MAGANA R, Mendes LST, Dinneen E, Al-Hammouri T, et al
    The LaserSAFE technique for margin assessment during radical prostatectomy: a feasibility study.
    BJU Int. 2026;138 Suppl 1.
    PubMed         Abstract available
    
    

    
    BMC Cancer

14. XU H, Ma Y, Ning X, Liu B, et al
    Development and validation of a preoperative grading system incorporating MRI and clinicopathological features to predict positive surgical margins in robot-assisted laparoscopic prostatectomy.
    BMC Cancer. 2026;26:523.
    PubMed         Abstract available
    
    
15. ABDLKADIR AS, Al-Adhami D, Moghrabi S, Sathekge MM, et al
    Beyond [(177)Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.
    BMC Cancer. 2026;26:551.
    PubMed         Abstract available
    
    
16. LUAN Y, Gao YQ, Huang TB, Zhu LY, et al
    Clinical value of intraoperative frozen section examination-assisted strategy in prostate biopsy: a comparative study of diagnostic efficiency and clinical practicality.
    BMC Cancer. 2026;26:646.
    PubMed         Abstract available
    
    
17. HAO X, Ye C, Lai W, Xu J, et al
    Urologic malignancy in renal transplant recipients: Analysis of OPTN/UNOS data from 2000 to 2022.
    BMC Cancer. 2026;26:805.
    PubMed         Abstract available
    
    
18. LOU Y, Fan D, Chen T, Xiong K, et al
    The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026;26:804.
    PubMed         Abstract available
    
    

    
    BMC Urol

19. NYONGOLE O, Munishi C, Kimu N, Shirima GV, et al
    Quality of services and patient reported outcomes for prostate cancer in Tanzania: the role of patients' satisfaction from a cross-sectional study.
    BMC Urol. 2026 Jul 2. doi: 10.1186/s12894-026-02231.
    PubMed         Abstract available
    
    
20. YILMAZ IO, Yilmaz O, Zubaroglu M, Kavak R, et al
    Comparative evaluation of the briganti nomogram, partin nomogram, mskcc nomogram and a machine learning-based model in predicting lymph node invasion before radical prostatectomy.
    BMC Urol. 2026;26:123.
    PubMed         Abstract available
    
    
21. MUSSGENS C, Roth B, Arnold N, Schneidewind L, et al
    Accidental transcutaneous displacement of a fiducial marker during transperineal prostate biopsy: a case report and narrative review.
    BMC Urol. 2026;26:115.
    PubMed         Abstract available
    
    
22. FRANSIS K, Bouziotis J, Tappero S, De Wachter S, et al
    Outcomes of Retzius-sparing robot-assisted radical prostatectomy in men aged >/= 75 years.
    BMC Urol. 2026;26:92.
    PubMed         Abstract available
    
    
23. JACKSON N, Elias E, Igenge J, Ottoman O, et al
    Utility of prostate-specific antigen density and its correlation with Gleason grade groups: a hospital-based cross-sectional study among patients with prostate-related urinary symptoms at Bugando Medical Centre, Mwanza, Tanzania.
    BMC Urol. 2026;26:101.
    PubMed         Abstract available
    
    
24. SEN V, Sarikaya EA, Sinirsiz C, Karabacak CA, et al
    How lesions proportional density shapes MRI cognitive fusion biopsy outcomes; finding the needle in the haystack.
    BMC Urol. 2026;26:46.
    PubMed         Abstract available
    
    
25. LIU Z, Wu J, Li Y, Lu Q, et al
    Day surgery mode of multi-modal image AI fusion targeted transperineal biopsy technique using electromagnetic navigation tracking system under local anesthesia.
    BMC Urol. 2026;26:40.
    PubMed         Abstract available
    
    
26. AKDAL DOLEK B, Besler MS
    Evaluation of large language models in assigning PI-RADS v2.1 categories for prostate MRI reports.
    BMC Urol. 2026;26:27.
    PubMed         Abstract available
    
    
27. BORDE T, Varble NA, Kenigsberg A, Hazen LA, et al
    Digital rectal exam vs. electronic "digitized" prostate exam.
    BMC Urol. 2025;26:2.
    PubMed         Abstract available
    
    

    
    Br J Cancer

28. YOON HS, Shu XO, Wu J, Sanderson M, et al
    Circulating metabolite biomarkers associated with prostate cancer risk in Black Americans: findings from the Southern Community Cohort Study.
    Br J Cancer. 2026 Jun 27. doi: 10.1038/s41416-026-03520.
    PubMed         Abstract available
    
    

    
    Cancer Imaging

29. PADDEN-MODI M, Taprogge J, Dutey-Magni P, Cauduro CGS, et al
    Predictive imaging biomarkers on whole-body diffusion-weighted MRI (WB-DWMRI) and [(68)Ga]GaPSMA-PET/CT for [(177)Lu]LuPSMA therapy in metastatic prostate cancer (mCRPC).
    Cancer Imaging. 2026;26:84.
    PubMed         Abstract available
    
    
30. IBRAHIM EA, Alper E
    When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [(1)(8)F]FDG in high-risk prostate cancer: dual-tracer cohort study.
    Cancer Imaging. 2026 Jul 2. doi: 10.1186/s40644-026-01084.
    PubMed         Abstract available
    
    

    
    Cancer Res

31. FILLEUR S, Volz K, Nelius T, Mirochnik Y, et al
    Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.
    Cancer Res. 2026;86:3363.
    PubMed        
    
    

    
    Endocrinology

32. GIOELI D
    Long Non-Coding RNAs Mediate Endocrine Signaling and Resistance in Prostate Cancer.
    Endocrinology. 2026 Jul 2:bqag076. doi: 10.1210.
    PubMed         Abstract available
    
    

    
    Eur Urol

33. FANTI S, Turco F, Tombal B, Walz J, et al
    Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.
    Eur Urol. 2026 Jul 3:S0302-2838(26)02230-X. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
34. VITI A, Scuderi S, Cucchiara V, Gandaglia G, et al
    Re: Hormone Therapy Use and Duration with Postoperative Radiotherapy for Recurrent Prostate Cancer: an Individual Patient Data Meta-analysis.
    Eur Urol. 2026 Jun 29:S0302-2838(26)02221-9. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
35. TAKAHASHI T
    Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur U
    Eur Urol. 2026 Jun 29:S0302-2838(26)02238-4. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    J Nucl Med

36. HEKIMSOY T, Sauter AP, Tauber R, Horn T, et al
    Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined (18)F-Flotufolastat PSMA PET and mpMRI.
    J Nucl Med. 2026 Jul 2:jnumed.125.271916. doi: 10.2967/jnumed.125.271916.
    PubMed         Abstract available
    
    
37. WIDJAJA L, Hornfeck J, Siegmund SC, Gildehaus FJ, et al
    Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [(177)Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics.
    J Nucl Med. 2026 Mar 26:jnumed.125.271859. doi: 10.2967/jnumed.125.271859.
    PubMed         Abstract available
    
    
38. METSER U, Bauman G, Rashid M, Mirshahvalad SA, et al
    Utility of PSMA PET/CT After an Initial Negative Scan: Results from a Prospective Multicenter PSMA PET Registry.
    J Nucl Med. 2026 Apr 16:jnumed.126.272204. doi: 10.2967/jnumed.126.272204.
    PubMed         Abstract available
    
    
39. MISHRA A, Lisok A, Mease RC, Novakova Z, et al
    PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.
    J Nucl Med. 2026 Apr 22:jnumed.125.271053. doi: 10.2967/jnumed.125.271053.
    PubMed         Abstract available
    
    
40. BUTTNER T, Hoffmann C, Essler M, Gartner F, et al
    Quantifying the Renal Impact of [(177)Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry.
    J Nucl Med. 2026;67:1086-1089.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

41. FRANCOLINI G, Di Cataldo V, Caini S, Garlatti P, et al
    SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.
    Lancet Oncol. 2026;27:830-838.
    PubMed         Abstract available
    
    

    
    Prostate

42. VERMA S, Gupta K, Qiao X, Shen DL, et al
    Microbial Differences in Prostate Lesions Between Black and White American Men.
    Prostate. 2026;86:1202-1215.
    PubMed         Abstract available
    
    
43. QUARTA L, Filzmayer M, Petix M, Orlandi F, et al
    Temporal Trends of Metastatic Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era in the United States.
    Prostate. 2026 Jul 2. doi: 10.1002/pros.70212.
    PubMed         Abstract available
    
    
44. SHEN J, Katz AJ, Xie Y, Chen RC, et al
    Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer.
    Prostate. 2026 Jul 2. doi: 10.1002/pros.70215.
    PubMed         Abstract available
    
    

    
    Radiology

45. ABIODUN-OJO OA, Jani AB, Goyal S, Lawal IO, et al
    (18)F-Fluciclovine or (68)Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial.
    Radiology. 2026;319:e251874.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum